SRT-100™: The Non-Surgical Basal Cell Carcinoma Treatment for Patients Facing Skin Cancer
Basal cell carcinoma is the most frequently occurring form of skin cancer, with more than 2.5 million new cases diagnosed in the U.S. each year. More than one in every three new cancers is a skin cancer, and the vast majority are basal cell carcinomas, which are usually caused by sun exposure, both cumulative as well as intense, occasional exposure.
This type of skin cancer appears as an abnormal, uncontrolled growth or lesion on the skin. Basal cell carcinomas often look like open sores, red patches, pink growths, shiny bumps, or scars. The good news is that basal cell carcinomas rarely spread (metastasize) beyond the original tumor site to become life threatening. However, if not treated promptly, they can become disfiguring.
There are several basal cell carcinoma treatment options available to patients, including: Mohs micrographic surgery, excisional surgery, electrosurgery, cryosurgery and laser surgery. These treatments all have one thing in common: the word surgery.
For patients with basal cell carcinoma, there is another option: Superficial Radiotherapy, or SRT, the non-surgical basal cell carcinoma treatment choice for removing non-melanoma skin cancer.
Sensus Healthcare’s SRT-100™ is a precise, pain-free, calibrated, low-dose of Superficial Radiotherapy that effectively destroys basal cell carcinomas. It doesn’t involve cutting, bleeding or stitching. There is no need for anesthesia, no risk of infection or scarring and no need for reconstructive plastic surgery. With the SRT-100™, patients heal quickly with no downtime or lifestyle restrictions following treatment.
The SRT-100™ is a safe and effective procedure that only takes minutes in the physician’s office. Cure rates of the SRT-100™ compete with those of surgical treatments, destroying skin cancer without any collateral damage to healthy skin cells.
If you have been diagnosed with skin cancer, ask your doctor about the revolutionary Sensus Healthcare SRT-100™ for basal cell carcinoma treatment. For more information on the SRT-100™, contact Sensus Healthcare today.